Local Anesthetics Overview
Local anesthetics are a class of drugs that reversibly block nerve conduction when applied to a specific area of the body, producing temporary loss of sensation without loss of consciousness. They are among the most commonly used drugs in medicine, with applications spanning surgery, dentistry, emergency medicine, obstetrics, and pain management. Understanding their pharmacology and maximum safe doses is essential for every clinician who administers these agents.
Local anesthetics are classified into two chemical families based on the bond connecting the aromatic ring to the intermediate chain: amino esters (procaine, chloroprocaine, tetracaine) and amino amides (lidocaine, bupivacaine, ropivacaine, mepivacaine, prilocaine). This classification has practical implications for allergy cross-reactivity and metabolism. Ester-type agents are metabolized by plasma cholinesterases and may produce para-aminobenzoic acid (PABA) as a metabolite, which can cause allergic reactions. Amide-type agents are metabolized by hepatic cytochrome P450 enzymes and have a much lower incidence of true allergic reactions.
The potency, onset, and duration of local anesthetics depend on their physicochemical properties, including lipid solubility (determines potency), protein binding (determines duration), and pKa (determines onset speed). Higher lipid solubility generally correlates with greater potency but also greater toxicity, which is why potent agents like bupivacaine have lower maximum dose limits compared to less potent agents like lidocaine.
Mechanism of Action: Sodium Channel Blockers
Local anesthetics work by blocking voltage-gated sodium channels in neuronal cell membranes. Under normal physiological conditions, nerve impulses are conducted through the sequential opening of sodium channels along the axon, allowing sodium ions to flow into the cell and depolarize the membrane. This wave of depolarization constitutes the action potential that transmits sensory and motor signals.
When a local anesthetic molecule binds to the intracellular portion of the sodium channel (specifically the alpha subunit in domain IV, segment 6), it prevents the conformational change necessary for channel opening. Without functional sodium channels, the nerve cannot generate or propagate action potentials, and signal transmission ceases. The block is reversible because the drug eventually dissociates from the channel and is cleared from the tissue by local blood flow.
An important clinical concept is differential nerve blockade: smaller, unmyelinated C fibers (which carry pain and temperature) are more susceptible to local anesthetic block than larger, myelinated A-alpha fibers (which carry motor signals). This is why patients may experience pain relief before motor weakness, and why sensory block typically outlasts motor block during recovery.
Individual Agent Profiles
Lidocaine
Lidocaine is the most widely used local anesthetic worldwide. It has intermediate potency and duration of action (1–2 hours without epinephrine, 2–3 hours with). Onset is rapid (2–5 minutes). It is versatile and can be used for infiltration, nerve blocks, epidural anesthesia, and topical application. Lidocaine also has antiarrhythmic properties and is used intravenously for ventricular arrhythmias. Maximum dose: 4.5 mg/kg without epinephrine, 7 mg/kg with epinephrine.
Bupivacaine
Bupivacaine is a long-acting, highly potent local anesthetic. Its duration of action is 4–8 hours, making it ideal for surgical anesthesia and postoperative pain management. However, bupivacaine has the highest cardiotoxicity potential among commonly used local anesthetics due to its strong affinity for cardiac sodium channels. Resuscitation from bupivacaine-induced cardiac arrest is notoriously difficult. Maximum dose: 2 mg/kg without epinephrine, 3 mg/kg with epinephrine.
Ropivacaine
Ropivacaine was developed as a safer alternative to bupivacaine. It is a pure S-enantiomer with less cardiotoxicity while maintaining similar duration and efficacy for most clinical applications. It also produces less motor block at lower concentrations, making it popular for labor epidural analgesia. Maximum dose: 3 mg/kg without epinephrine, 3.5 mg/kg with epinephrine.
Mepivacaine
Mepivacaine has properties similar to lidocaine but with a slightly longer duration of action (2–3 hours without epinephrine). It is commonly used in dentistry and for peripheral nerve blocks. Mepivacaine has less vasodilatory effect than lidocaine, which means it can be used without epinephrine in situations where vasoconstriction is undesirable. Maximum dose: 4.4 mg/kg without epinephrine, 6.6 mg/kg with epinephrine.
Prilocaine
Prilocaine has the lowest systemic toxicity of all the amide local anesthetics, making it suitable for techniques requiring large volumes. However, its metabolite o-toluidine can cause methemoglobinemia at high doses (typically above 600 mg), limiting its use. It is a key component of EMLA cream (eutectic mixture of local anesthetics) combined with lidocaine. Maximum dose: 6 mg/kg without epinephrine, 8 mg/kg with epinephrine.
Procaine
Procaine (Novocain) is an ester-type local anesthetic that was historically the first injectable local anesthetic used in clinical practice. It has low potency and short duration of action (30–60 minutes). While largely replaced by amide agents for most applications, it remains useful for infiltration anesthesia and as a test dose for ester allergy evaluation. Maximum dose: 7 mg/kg without epinephrine, 9 mg/kg with epinephrine.
Maximum Dose Reference Table
| Agent | mg/kg (no epi) | mg/kg (with epi) | Max Single Dose (no epi) | Max Single Dose (with epi) |
|---|---|---|---|---|
| Lidocaine | 4.5 | 7 | 300 mg | 500 mg |
| Bupivacaine | 2 | 3 | 175 mg | 225 mg |
| Ropivacaine | 3 | 3.5 | 200 mg | 250 mg |
| Mepivacaine | 4.4 | 6.6 | 400 mg | 440 mg |
| Prilocaine | 6 | 8 | 400 mg | 600 mg |
| Procaine | 7 | 9 | 500 mg | 600 mg |
Local Anesthetic Systemic Toxicity (LAST)
Local anesthetic systemic toxicity (LAST) is a potentially life-threatening complication that occurs when local anesthetic blood levels become high enough to affect the central nervous system and cardiovascular system. LAST can result from inadvertent intravascular injection, excessive dosing, rapid absorption from highly vascular sites, or impaired drug metabolism.
The classic presentation follows a progression from CNS symptoms to cardiovascular collapse. Early CNS symptoms include perioral numbness, metallic taste, tinnitus, visual disturbances, dizziness, and agitation. As levels rise, patients may develop muscle twitching, seizures, and loss of consciousness. Cardiovascular toxicity manifests as bradycardia, conduction block, hypotension, and eventually cardiac arrest. However, this classic progression is not always observed; some patients present with cardiovascular collapse without preceding CNS symptoms, particularly with bupivacaine.
Prevention of LAST involves careful dose calculation (never exceeding maximum recommended doses), aspiration before injection, incremental injection with frequent aspiration, use of ultrasound guidance for nerve blocks, and maintaining verbal contact with the patient during injection. All practitioners who administer local anesthetics should have immediate access to lipid emulsion and be familiar with the LAST treatment algorithm.
Lipid Emulsion Rescue
Intravenous lipid emulsion (ILE) therapy has revolutionized the management of severe LAST. The mechanism of action involves a "lipid sink" effect, where the lipid particles sequester lipophilic local anesthetic molecules from affected tissues, particularly the heart and brain. ILE also provides a direct cardiotonic effect by supplying fatty acids as an energy substrate for the myocardium.
The recommended protocol for lipid rescue in LAST involves an initial bolus of 20% lipid emulsion (Intralipid) at 1.5 mL/kg over 1 minute, followed by an infusion of 0.25 mL/kg/min. The bolus may be repeated 1–2 times for persistent cardiovascular collapse, and the infusion rate can be doubled if needed. The maximum recommended dose is approximately 12 mL/kg. ACLS protocols should be followed simultaneously, but epinephrine doses should be reduced (less than 1 mcg/kg) and vasopressin, calcium channel blockers, and beta-blockers should be avoided.
Benefits of Epinephrine
Epinephrine (adrenaline) is frequently added to local anesthetic solutions at concentrations of 1:100,000 to 1:200,000. The addition of epinephrine provides several important clinical benefits through its alpha-1 adrenergic vasoconstrictor effect on local blood vessels.
- Reduced systemic absorption: Vasoconstriction slows the rate of local anesthetic absorption into the bloodstream, reducing peak plasma levels and lowering the risk of systemic toxicity. This is why maximum doses are higher when epinephrine is added.
- Prolonged duration: By reducing blood flow to the injection site, epinephrine keeps the anesthetic in contact with nerve fibers for a longer period, extending the duration of block by 50–100%.
- Improved block quality: Higher local tissue concentrations result in more complete neural blockade.
- Reduced bleeding: Local vasoconstriction decreases surgical site bleeding, improving visibility.
- Intravascular injection marker: An increase in heart rate of 20% or more after injection suggests inadvertent intravascular placement.
Epinephrine should be avoided in end-artery territories (fingers, toes, ears, nose, penis) due to the risk of ischemia, although recent evidence suggests that low concentrations in digital blocks are safe. It should also be used cautiously in patients with severe cardiovascular disease, uncontrolled hypertension, or hyperthyroidism.
Dose Calculation Formulas
For example, a 70 kg patient receiving 1% lidocaine without epinephrine: Max dose = min(70 × 4.5, 300) = 300 mg. Max volume = 300 / (1 × 10) = 30 mL.
Frequently Asked Questions
Why is the maximum dose lower for bupivacaine?
Bupivacaine is significantly more potent and cardiotoxic than other local anesthetics. It has high lipid solubility and strong binding affinity for cardiac sodium channels, meaning even small amounts reaching the bloodstream can cause severe cardiovascular toxicity. The lower dose limits reflect this narrow margin of safety.
Can I mix different local anesthetics?
Yes, but the toxicities are additive. If you use 50% of the maximum dose of lidocaine, you can only use up to 50% of the maximum dose of the second agent. Think of it as a shared toxicity budget. This is particularly important when combining agents for different onset/duration profiles.
What concentration should I use?
Lower concentrations (0.25–0.5%) are generally preferred for field blocks and large-volume infiltration, as they allow greater volume for wider coverage while staying within safe dose limits. Higher concentrations (1–2%) are used for nerve blocks and procedures requiring dense anesthesia. The choice depends on the specific procedure and block type.
How does obesity affect dosing?
Maximum dose calculations should generally use ideal or lean body weight rather than total body weight in obese patients. Using total body weight can result in excessive dosing because the drug distributes primarily into lean tissues, not adipose tissue. Clinical judgment is essential, and some practitioners use an adjusted body weight for morbidly obese patients.
What are the signs of LAST?
Early signs include perioral numbness, metallic taste, tinnitus, dizziness, and visual changes. As toxicity progresses, patients may develop muscle twitching, seizures, respiratory depression, bradycardia, arrhythmias, and cardiovascular collapse. Always maintain verbal contact during injection and have lipid emulsion immediately available.
Is it safe to use epinephrine in digital blocks?
Modern evidence from multiple large studies has shown that low-concentration epinephrine (1:100,000 to 1:200,000) in digital blocks does not cause finger ischemia in healthy patients. However, it should be avoided in patients with peripheral vascular disease, Raynaud's phenomenon, or sickle cell disease. Many practitioners now routinely use epinephrine in digital blocks for the benefits of prolonged anesthesia and reduced bleeding.